Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

9.3%

4 terminated/withdrawn out of 43 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

21%

9 trials in Phase 3/4

Results Transparency

39%

7 of 18 completed trials have results

Key Signals

12 recruiting7 with results

Enrollment Performance

Analytics

Phase 2

13(48.1%)

Phase 3

5(18.5%)

Phase 4

4(14.8%)

Phase 1

3(11.1%)

N/A

2(7.4%)

27Total

Phase 2(13)

Phase 3(5)

Phase 4(4)

Phase 1(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (43)

Showing 20 of 43 trials

NCT06679829Phase 2Recruiting

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Role: collaborator

NCT05684692Phase 2Recruiting

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Role: collaborator

NCT05791708Active Not Recruiting

Cold Agglutinin Disease Real World Evidence Registry

Role: lead

NCT03708900Phase 2Recruiting

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Role: lead

NCT06295952Phase 2Recruiting

A Study of Pasireotide in People With Prolactinoma

Role: collaborator

NCT07104812Phase 2Recruiting

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Role: collaborator

NCT07312643Phase 1Completed

Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

Role: lead

NCT06344143Recruiting

Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma

Role: collaborator

NCT07247162Phase 4Not Yet Recruiting

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

Role: lead

NCT05382156Active Not Recruiting

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Role: lead

NCT05928390Phase 2Active Not Recruiting

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Role: lead

NCT06430528Recruiting

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

Role: collaborator

NCT05080790Phase 2Completed

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

Role: collaborator

NCT07046663Not Yet Recruiting

Long-term Assessment of Chlormethine Gel in Mycosis Fungoides

Role: collaborator

NCT04276558Phase 2Completed

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Role: lead

NCT06447376Phase 1Recruiting

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Role: collaborator

NCT05040178Recruiting

An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

Role: lead

NCT05633953Completed

Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

Role: lead

NCT03606408Phase 2Completed

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Role: lead

NCT05265442Completed

Real-life Observational Study of Cancer Pain Management With Methadone

Role: lead